<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136238">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980680</url>
  </required_header>
  <id_info>
    <org_study_id>Agonist5</org_study_id>
    <nct_id>NCT01980680</nct_id>
  </id_info>
  <brief_title>The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients</brief_title>
  <acronym>GnRHa trigger</acronym>
  <official_title>The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Humaidan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After hCG trigger a large amount of exogenous progesterone is used for luteal phase support
      in many countries until 10th week of gestation. Instead we suggest the use of two small
      doses of hCG after the trigger during the early luteal phase after GnRHa trigger, promoting
      the endogenous progesterone production from the corpora lutea (CL).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ongoing pregnancy rate per patient</measure>
    <time_frame>10th week of gestation.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hCG trigger Pregnyl (hCG) and Progesterone and Estradiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <arm_group_label>Agonist trigger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone and Estradiol</intervention_name>
    <arm_group_label>hCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 and 40

          -  Normal menstrual cycles: 25-34 days

          -  Oligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam
             criteria 2004)

          -  BMI &gt;18 and &lt;35 kg/m2

        Exclusion Criteria:

          -  Patients with &gt;14 follicles on day of trigger

          -  Previous hyperresponse with OHSS development

          -  Previous low response (less than 3 oocytes on a high dose of FSH stimulation)

          -  Endocrine disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Peter Humaidan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
